Preview

 Пульмонология

Расширенный поиск

Фенотип хронической обструктивной болезни легких с частыми обострениями и современная противовоспалительная терапия

https://doi.org/10.18093/0869-0189-2013-0-1-68-76

Полный текст:

Аннотация

Фенотип хронической обструктивной болезни легких с частыми обострениями и современная противовоспалительная терапия.

Об авторах

З. Р. Айсанов
ФГБУ "НИИ пульмонологии"
Россия

д. м. н., проф., зав. отделом клинической физиологии и клинических исследований 

105077, Москва, ул. 11–я Парковая, 32, корп. 4



Е. Н. Калманова
ГБОУ ВПО РНИМУ им. Н.И.Пирогова
Россия

к. м. н., доцент кафедры госпитальной терапии педиатрического факультета 

117997, Москва, ул. Островитянова, 1



О. Ю. Стулова
ФГБУ "НИИ пульмонологии"
Россия

зав. лабораторией 

105077, Москва, ул. 11–я Парковая, 32, корп. 4



Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. Updated 2013. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf

2. World Health Organization. Chronic Obstructive Pulmonary Disease Fact Sheet. 2012. www.who.int/mediacentre/factsheets/fs315

3. Celli B.R., Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946.

4. Donaldson G.C., Wedzicha J.A. COPD exacerbations. 1: Epidemiology. Thorax 2006; 61 (2): 164–168.

5. Pauwels R., Calverley P., Buist A.S. et al. COPD exacerbations: the importance of a standard definition. Respir. Med. 2004; 98 (2): 99–107.

6. Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (5): 1608–1613.

7. Hurst J.R., Perera W.R., Wilkinson T.M. et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 71–78.

8. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–796.

9. Perera W.R., Hurst J.R., Wilkinson T.M. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29 (3): 527–534.

10. Miravitlles M., Guerrero T., Mayordomo C. et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiplelogistic regression analysis. Respiration 2000; 67: 495–501.

11. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.

12. Soler–Cataluna J.J., Rodriguez–Roisin R. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious? COPD 2010; 7: 276–284.

13. Tashkin D.P. Frequent exacerbations of chronic obstructive pulmonary disease – a distinct phenotype? N. Engl. J. Med. 2010; 363: 1183–1184.

14. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.

15. Quint J.K, Baghai–Ravary R., Donaldson G.C., Wedzicha J.A. Relationship between depression and exacerbations in COPD. Eur. Respir. J. 2008; 32: 53–60.

16. Soler J.J., Sanchez L., Roman P. et al. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir. Med. 2004; 98: 318–329.

17. Soler J.J., Sanchez L., Latorre M. et al. The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization. Arch. Bronconeumol. 2001; 37: 375–381.

18. Soler–Cataluña J.J., Martinez–Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–931.

19. Esteban C., Quintana J.M., Aburto M. et al. Predictors of mortality in patients with stable COPD. J. Gen. Intern. Med. 2008; 23: 1829–1834.

20. Soler–Cataluña J.J., Martinez–Garcia M.A., Sanchez L. et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir. Med.2009; 103: 692–699.

21. Alfageme I., Reyes N., Merino M. et al. The effect of airflow limitation on the cause of death in patients with COPD. Chron. Respir. Dis. 2010; 7: 135–145.

22. Dewan N.A., Rafique S., Kanwar B. et al. Acute exacerbation of COPD: factors associated with poor outcome. Chest 2000; 117: 662–671.

23. Bhowmik A., Seemungal T.A.R., Sapsford R.J., Wedzicha J.A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exac– erbations. Thorax 2000; 55: 114–120.

24. Miravitlles M., Marin A., Monso E. et al. Colour of sputum is a marker of bacterial colonization in COPD. Respir. Res. 2010; 11: 58.

25. Burgel P.R., Nesme–Meyer P., Chanez P. et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975–982.

26. Patel I.S., Seemungal T.A.R., Wiks M. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759–764.

27. Tumkaya M., Atis S., Ozge C. et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir. Med. 2007; 101: 729–737.

28. Wan E.S., DeMeo D.L., Hersh C.P. et al. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir. Med. 2011; 105: 588–594.

29. Decramer M., Gosselink R., Troosters T. et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur. Respir J. 1997; 10: 417–423.

30. Donaldson G.C., Hurst J.R., Smith C.J. et al. Increased risk of myocardial infarction and stroke following exacerbation of chronic obstructive pulmonary disease. Chest 2010; 137: 1091–1097.

31. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir. Med. 2011; 105: 1118–1128.

32. Martinez–Garcia M.A., Soler–Cataluña J.J., Donat Y. et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest 2011; 140: 1130–1137.

33. Patel I.S., Vlahos I., Wilkinson T.M.A. et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 400–407.

34. Bourbeau J., Ford G., Zackon H. et al. Impact on patients' health status following early identification of a COPD exacerbation. Eur. Respir. J. 2007; 30: 907–913.

35. Doll H., Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005; 23: 345–363.

36. Donaldson G.C., Hurst J.R., Smith C.J. et al. Increased risk of myocardial infarction and stroke following exacerbation of chronic obstructive pulmonary disease. Chest 2010; 137: 1091–1097.

37. Bhowmik A., Seemungal T.A.R., Sapsford R.J., Wedzicha J.A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114–120.

38. Suissa S., Dell'aniello S., Ernst P. Long–term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957–963.

39. Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374 (9691): 685–694.

40. Fabbri L.M., Calverley P.M., Izquierdo–Alonso J.L. et al. Roflumilast in moderate–to–severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374 (9691): 695–703.

41. Bateman E.D., Rabe K.F., Calverley P.M. et al. Roflumilast with long–acting beta2–agonists for COPD: influence of exacerbation history. Eur. Respir. J. 2011; 38 (3): 553–560.

42. Rennard S.I., Calverley P.M., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast –the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18.

43. Grootendorst D.C., Gauw S.A., Verhoosel R.M. et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62 (12): 1081–1087.

44. Wedzicha J.A., Rabe K.F., Martinez F.J. et al. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype (e–publication on http://journal.publications.chestnet.org).

45. Postma D., Anzueto A., Calverley P. et al. A new perspective on optimal care for patients with COPD. Prim. Care Respir. J. 2011; 20 (2): 205–209.

46. Rabe K.F., Wedzicha J.A. Controversies in treatment of chronic obstructive pulmonary disease. Lancet 2011; 378 (9795): 1038–1047.

47. Agusti A., Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 184: 507–513.

48. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363 (12): 1128–1138.

49. Singh S., Amin A.V., Loke Y.K. Long–term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch. Intern. Med. 2009; 169: 219–229.

50. Quint J.K., Donaldson G.C., Hurst J.R. et al. Predictive accuracy of patient–reported exacerbation frequency in COPD. Eur. Respir. J. 2011; 37: 501–507.


Для цитирования:


Айсанов З.Р., Калманова Е.Н., Стулова О.Ю. Фенотип хронической обструктивной болезни легких с частыми обострениями и современная противовоспалительная терапия.  Пульмонология. 2013;(1):68-76. https://doi.org/10.18093/0869-0189-2013-0-1-68-76

For citation:


Aisanov Z.R., Kalmanova E.N., Stulova O.Y. Phenotype of chronic obstructive pulmonary disease with frequent exacerbations and current anti–inflammatory therapy. Russian Pulmonology. 2013;(1):68-76. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-1-68-76

Просмотров: 383


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)